

7. (New) A composition according to claim 2, wherein the allergen is adsorbed onto the tyrosine.
8. (New) A composition according to claim 2, wherein the allergen is coated with and adsorbed onto the tyrosine.
9. (New) A method according to claim 3, wherein the tyrosine, the optionally modified allergen, and the 3-DPML are administered in a single pharmaceutical composition.
10. (New) A method according to claim 9, wherein the allergen is coated with and/or adsorbed onto the tyrosine.
11. (New) A method according to claim 9, wherein the allergen is adsorbed onto the tyrosine.
12. (New) A method according to claim 9, wherein the allergen is coated with and adsorbed onto the tyrosine.
13. (New) A process for preparing an allergen formulation, comprising: (a) mixing an aqueous solution of an allergen with a solution of tyrosine in a strong aqueous acid; (b) neutralizing the mixture of solutions, thereby co-precipitating tyrosine and the allergen; (c) mixing the product of step (b) with 3-DMPL; and optionally (d) adding a physiologically acceptable carrier.
14. (New) A process for preparing an allergen formulation, comprising: (a) modifying an allergen by reaction with a cross-linking agent, to provide a modified allergen; (b) mixing an aqueous solution of the modified allergen with a solution of tyrosine in a strong aqueous acid; (c) neutralizing the mixture of solutions, thereby co-precipitating tyrosine and the modified allergen; (d) mixing the product of step (c) with 3-DMPL; and optionally (e) adding a physiologically acceptable carrier.--